News
Humana Announces New Agreement with Interwell Health That Expands Comprehensive Care for Members Living with Chronic Kidney Disease
Leading health and well-being company Humana Inc. (NYSE: HUM), and kidney care management company Interwell Health, have announced a new value-based care agreement in 13 states for most Humana
EQS-News: Abivax appoints Patrick Malloy as Senior Vice President Investor Relations
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
EQS-News: Formycon hosts conference call on financial and earnings position for H1 2023
Vistagen Appoints Cindy Anderson as Chief Financial Officer
Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Premier, Inc. Reports Fiscal-Year 2023 Fourth-Quarter and Full-Year Results
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal year 2023 fourth quarter and full year ended June 30, 2023
U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F
Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors has appointed two new directors. Dr. Karen Smith and Jeffrey A. Bailey joined
NanoString Platforms Advance Groundbreaking Studies of Immune Response in Pig-to-Human Organ Transplants
NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, announced today that a team of globally renowned researchers
EQS-News: Abivax secures up to EUR 150M from two structured debt financing transactions
Humana Supports Health Equity, Community Organizations via National Grants
Humana (NYSE: HUM) announced sixteen community-based organizations across the nation will receive grants totaling over $121,500. With millions of medical and specialty care members across the
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Humana Ranked No. 1 Among Health Insurers for Customer Experience
For the third year in a row, Humana ranked No. 1 among health insurers for customer experience (CX) by Forrester*. Humana received the highest CX Index™ score among Health Insurers in Forrester’s
Silence Therapeutics Reports Second Quarter 2023 Results
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Agilent Reports Third-Quarter Fiscal Year 2023 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.67 billion for the third quarter ended July 31, 2023, a decrease of 2.7% compared to the third quarter of 2022 and a decrease of
Researchers Use the Simulations Plus DILIsym® Platform to Predict Safety of Combined CBD and VPA Treatment
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today shared an article published in the July 2023
Dexcom Canada Achieves Great Place to Work® Certification for Second Consecutive Year
Dexcom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (rtCGM), is proud to announce that for the second consecutive year, it has been certified as a Great Place to
Pfizer’s ELREXFIO™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to ELREXFIO™ (elranatamab-bcmm) for the treatment of adult patients with relapsed
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Premier, Inc. Declares Quarterly Cash Dividend
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.21 per share of Class A common
Subsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial Results
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous